ASX Announcements
Notification of cessation of securities - CSL
Appendix 3H (Notification of cessation of securities)
- May 3, 2024
- 4 pages
Notification of cessation of securities - CSL
Appendix 3H (Notification of cessation of securities)
- Apr 5, 2024
- 4 pages
April
This fundie says CSL is a $500 stock
ECP Asset Management’s Sam Byrnes expects the blood plasma collector’s return on capital to substantially improve and remains bullish on IDP Education even though its share price has tumbled this year.
- Joanne Tran
The eight stocks most loved by Australia’s best fund managers
Despite the headwinds, CSL is still loved by the top stock pickers. CBA and BHP are also widely held – but not as widely as expected.
- Joshua Peach
Macquarie tips CSL shares to hit $500
Some of the biotechnology giant’s shareholders are sceptical about the investment bank’s call, which is detailed to clients in a 55-page note.
- Updated
- Alex Gluyas
March
Blood giant CSL works up $US1 billion-plus bond deal; banks mandated
CSL has a host of top-tier investment banks working on the deal, namely Bank of America, Citi, JPMorgan and HSBC.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Dick Humphry, inventor of shareholder democracy, dies at 85
A man whose habits and approach were set in the “old school”, Richard Humphry nevertheless led a technology-driven revolution in Australia’s financial markets.
- Andrew Clark
February
Why we can’t agree on WFH | Where mortgage stress is rising | What to drink mid-air
Read everything that’s happened in the news so far today.
The juggernaut keeping CSL’s valuation pumping despite Ozempic threat
CSL managed to shrug off the Ozempic effect and this week’s setback linked to a disappointing phase three trial thanks to its CSL Behring blood products business.
- Updated
- Ben Potter
- Opinion
- Chanticleer
What we learnt from CSL, Challenger, Seek and Breville’s results
Investors in CSL and Breville have growth questions on their mind, while Seek’s downgrade sent shares skidding. Meanwhile, at Challenger, a bro-mance is brewing.
- James Thomson and Anthony Macdonald
Macquarie’s top earner departs | ATO staff in GST fraud | ANZ to cut 170 jobs
Read everything that’s happened in the news so far today.
CSL shares slide on ‘dampened’ Vifor outlook
News of the downgraded outlook for Vifor overshadowed an 11 per cent increase in underlying first-half group net profit and a similar increase in the interim dividend.
- Ben Potter
Why analysts love these eight medtech stocks
The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.
- Tom Richardson
Right to disconnect a ‘challenge’ | CSL’s drug setback | Best economy class airlines
Read everything that’s happened in the news so far today.
- Opinion
- Chanticleer
Drug trial failure gives CSL $8b of heart palpitations
The study for CSL’s new heart attack drug was the biggest in its storied history. But high hopes have turned to major disappointment.
- James Thomson
$7b wiped off CSL shares after ‘second heart attack’ drug setback
Head of research and development Bill Mezzanotte said in November that CSL112 was one of three potential blockbuster drugs in its development pipeline.
- Ben Potter
January
- Opinion
- Chanticleer
Why Australia’s biggest and oldest LIC defied the Ozempic sell-off
Australian Foundation Investment Company boss Mark Freeman says buying CSL and Resmed amid last year’s Ozempic rout was part of a tried-and-true strategy.
- James Thomson
- Opinion
- Chanticleer
Cybersecurity is the No.1 risk not getting the attention it deserves
Australia’s top CEOs say the risk of cyberattacks and the healthcare demands of an ageing population are being ignored or underplayed.
- James Thomson and Anthony Macdonald
December 2023
- Opinion
- Chanticleer
Top investors name 11 long-term stock picks
Healthcare, digitisation and resources are the big themes that dominate the list of stock picks from top fund managers.
- James Thomson
BHP at $100, shorting banks, Qantas chaos: the best of Monday Fundie
From Regal to Ellerston Capital and Morningstar, the 48 fund managers profiled by the Financial Review were early, wrong and on the money in 2023.
- Jonathan Shapiro and Sarah Jones
- Exclusive
- Hedge funds
Hedge funds divided on CSL as Perpetual and Pendal place opposing bets
Portfolio managers within the same wealth giant are at odds over the outlook for one of the ASX’s largest and widely held stocks.
- Joshua Peach
November 2023
Melbourne earns top marks for research
The vice-chancellor’s pedigree and the blossoming of the Melbourne Biomedical Precinct help to explain why Melbourne University has ranked number one in both the research and reputation categories.
- Patrick Durkin
